Top Markets
#1 Celer Network Celer Network +49.10%
#2 Gravity Gravity +24.44%
#3 Galxe Galxe +23.88%
#4 ICON ICON +13.39%
#5 MemeCore MemeCore +13.25%
#6 Cartesi Cartesi +12.87%
#7 Zilliqa Zilliqa +10.95%
#8 Genius Genius +10.65%
#9 Ontology Gas Ontology Gas +9.33%
#10 CyberDEX CyberDEX +7.13%
Coin of the day
Celer Network Celer Network
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Classement en actions #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
Prix de l'action
$0.1559364
Dernière synchronisation: 2026-09-18
Capitalisation boursière
$195.17K
Changement (1 jour)
6.60%
Changement (1 an)
-30.91%
Pays
GB
Échange Fusion Antibodies plc (FAB)

Catégorie

Healthcare
Ratio P/S pour Fusion Antibodies plc (FAB)
Ratio P/S au September 2026 TTM : 7.25
Selon les derniers rapports financiers et le cours de l'action de Fusion Antibodies plc, le ratio cours/ventes actuel (TTM) est 7.25. À la fin de 2024, le ratio P/S était de 1.88.
Historique du ratio P/S pour Fusion Antibodies plc de 2013 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
2026 (TTM) 7.25 141.79%
2025 3.00 59.38%
2024 1.88 -45.47%
2023 3.45 6.43%
2022 3.24 -66.20%
2021 9.60 78.11%
2020 5.39 86.72%
2019 2.89 -54.34%
2018 6.32 -55.67%
2017 14.25 -22.61%
2016 18.42 -38.61%
2015 30.00 -20.48%
2014 37.73 -43.99%
2013 67.37 0.00%
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.44 43.99%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
12.01 65.53%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
26.12 260.14%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.76 -48.23%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH